Publication Year

Chen Q, Jiang X, Hedgeman E, Knutson K, Gillespie B, Hong B, Lepkowski JM, Franzblau A, et al. 2013. Estimation of age-and sex-specific background human serum concentrations of PCDDs, PCDFs, and PCBs in the UMDES and NHANES populations. Chemosphere 91(6):817-23; doi: 10.1016/j.chemosphere.2013.01.078. PMID: 23466097.

MacDonell MM, Haroun LA, Teuschler LK, Rice ER, Hertzberg RC, Butler JP, Chang Y, Clark S, Johns AP, Perry CS, Garcia SS, Jacobi JH, Scofield MA. 2013. Cumulative risk assessment toolbox: Methods and approaches for the practitioner. J Toxicol 2013:310904; doi: 10.1155/2013/310904. PMID: 23762048.

Proctor DM, Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC. 2013. Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. J Appl Toxicol 33(12):1395-1406; doi: 10.1002/jat.2799.

Meddings J, Reichert H, Rogers MAM, Hofer T, McMahon LF. Risk-adjusting hospital-acquired pressure ulcer rates from claims data: Teaching hospitals beware. Presented at the 2013 Society of General Internal Medicine Annual Meeting, Denver, CO, April 2013.

Covington TR, Ruark CD, Yu KO, Gearhart JM. Human lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model. Poster presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Reddick H. Air quality along the Texas Gulf Coast. Poster, Society of Toxicology 52^nd Annual Meeting, San Antonio, TX, 2013.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Thompson CM, Kirman CR, Proctor DM, Suh M,Hays SM, Haws LC, Harris MA. A chronic oral reference dose for hexavalent chromium. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Haws L, Hixon G, DeVito M, Walker N, Kuriakose L, Harris M, Birnbaum L, Wikoff D. Development of weighted distributions of relative potency estimates for dioxin-like compounds. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Suh M, Thompson CM, Hixon JG, Harris MA, Kirman CR, Hays S, Haws LC, Proctor DM. Potential involvement of oxidative stress and iron disturbance in the development of oral cavity tumors in rats exposed to hexavalent chromium. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Wikoff D, Fitzgerald L, Haws L, Harris M. Health-based framework for evaluating the safety of hydraulic fracturing products. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Lamm SH, Britt JK, James RC. Multiple myeloma risk and benzene exposure among pliofilm workers – A re-analysis using an internal reference group. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX, March 2013.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3):244-274; doi: 10.3109/10408444.2013.768596. PMID: 23445218.

Belova A, Narayan T, Brown L, Haskell J, Bozeman S, Lamb J. A framework to assess aflatoxin public health impacts in developing countries with application to Nigeria and Tanzania. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Brown L, Lynch M, Post E, Belova A. Determine a concentration response relationship suitable for estimating adult benefits of reduced lead exposure. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Karchapati L, Bednar KJ, Adams DE, Wu Y, Mitter RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM. 2013. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun 47:94–103.

Shah F, Greene N. 2013. Analysis of Pfizer compounds in EPA’s ToxCast chemicals-assay space. Chem Res Toxicol 27(1):86-98; doi: 10.1021/tx400343t. PMID: 24328225.

Naven RT, Swiss R, Klug-McLeod J, Will Y, Greene N. 2013. The development of structure-activity relationships for mitochondrial dysfunction: Uncoupling of oxidative phosphorylation. Toxicol Sci 131(1):271-278; doi: 10.1093/toxsci/kfs279. PMID: 22977170.

Urban JD, Carakostas MC, Brusick DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient? Food Chem Toxicol 51(Jan):386-390; doi: 10.1016/j.fct.2012.10.016. PMID: 23103588.